Gabather was founded in 2014 as a result of more than ten years of collaborative research between Lund University (Sweden) and the Research Institute of Biological Chemistry in Roskilde (Denmark). The aim of the company is to develop novel small molecule drugs to treat diseases with an origin in the central nervous system. Gabather founders are the Forskarpatent fund together with scientists Olov Sterner and Mogens Nielsen.